JP2019500894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500894A5 JP2019500894A5 JP2018543279A JP2018543279A JP2019500894A5 JP 2019500894 A5 JP2019500894 A5 JP 2019500894A5 JP 2018543279 A JP2018543279 A JP 2018543279A JP 2018543279 A JP2018543279 A JP 2018543279A JP 2019500894 A5 JP2019500894 A5 JP 2019500894A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- variant
- seq
- domain
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021133074A JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562251052P | 2015-11-04 | 2015-11-04 | |
| US62/251,052 | 2015-11-04 | ||
| PCT/US2016/060724 WO2017079694A2 (en) | 2015-11-04 | 2016-11-04 | Chimeric antigen receptors targeting her2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021133074A Division JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500894A JP2019500894A (ja) | 2019-01-17 |
| JP2019500894A5 true JP2019500894A5 (enExample) | 2019-12-19 |
| JP6932709B2 JP6932709B2 (ja) | 2021-09-08 |
Family
ID=58662864
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543279A Expired - Fee Related JP6932709B2 (ja) | 2015-11-04 | 2016-11-04 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
| JP2021133074A Active JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
| JP2023065384A Withdrawn JP2023100653A (ja) | 2015-11-04 | 2023-04-13 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021133074A Active JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
| JP2023065384A Withdrawn JP2023100653A (ja) | 2015-11-04 | 2023-04-13 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11197919B2 (enExample) |
| EP (2) | EP4074731A1 (enExample) |
| JP (3) | JP6932709B2 (enExample) |
| KR (1) | KR20180083874A (enExample) |
| CN (2) | CN116063574A (enExample) |
| AU (2) | AU2016349722A1 (enExample) |
| BR (1) | BR112018009129A2 (enExample) |
| CA (1) | CA3004306A1 (enExample) |
| ES (1) | ES2909973T3 (enExample) |
| IL (2) | IL259120B (enExample) |
| MX (2) | MX2018005674A (enExample) |
| RU (1) | RU2753695C2 (enExample) |
| WO (1) | WO2017079694A2 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210014210A (ko) | 2014-05-15 | 2021-02-08 | 내셔널 유니버시티 오브 싱가포르 | 변형된 천연 살해 세포 및 그의 용도 |
| US11197919B2 (en) * | 2015-11-04 | 2021-12-14 | City Of Hope | Chimeric antigen receptors targeting HER2 |
| KR20180105709A (ko) | 2016-02-05 | 2018-09-28 | 시티 오브 호프 | 중추 신경계의 암의 치료를 위한 조작된 t 세포의 투여 |
| US20200095547A1 (en) * | 2016-12-02 | 2020-03-26 | Darya ALIZADEH | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors |
| CN110121505B (zh) | 2016-12-28 | 2023-08-01 | 株式会社绿十字细胞治疗 | 嵌合抗原受体和表达其的自然杀伤细胞 |
| EP4491234A3 (en) | 2017-02-08 | 2025-04-09 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| BR112019017197A2 (pt) | 2017-02-20 | 2020-04-14 | Dragonfly Therapeutics, Inc. | proteínas que se ligam a her2, nkg2d e cd16 |
| CA3056439A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| AU2018245749A1 (en) | 2017-03-27 | 2019-10-03 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| AU2018370195B2 (en) * | 2017-11-14 | 2022-01-13 | Green Cross Lab Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN109608547B (zh) * | 2017-12-29 | 2022-03-15 | 郑州大学第一附属医院 | 表达Her2的嵌合抗原受体、慢病毒表达载体及其应用 |
| PE20220278A1 (es) | 2018-02-08 | 2022-02-25 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d |
| AU2019218125B2 (en) | 2018-02-08 | 2025-03-13 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| WO2019155286A2 (en) * | 2018-02-09 | 2019-08-15 | National University Of Singapore | Adhesion receptor constructs and uses thereof in natural killer cell immunotherapy |
| SG11202007156QA (en) | 2018-02-09 | 2020-08-28 | Nat Univ Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| MX2020008287A (es) * | 2018-02-11 | 2021-01-08 | Univ California | Células t con receptor de antígeno quimérico (car-t) y enfermedades autoinmunes. |
| SG10201801219VA (en) | 2018-02-13 | 2019-09-27 | Agency Science Tech & Res | Anti-HER2 Antibodies |
| TW201942134A (zh) | 2018-02-20 | 2019-11-01 | 美商蜻蜓醫療公司 | 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法 |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2019222579A1 (en) * | 2018-05-17 | 2019-11-21 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with myd88 and cd40 costimulatory domains |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| KR20250112921A (ko) | 2018-08-08 | 2025-07-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202190468A1 (ru) | 2018-08-08 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения |
| US12486514B2 (en) | 2018-08-29 | 2025-12-02 | National University Of Singapore | Method to specifically stimulate survival and expansion of genetically-modified immune cells |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| US20230065784A1 (en) | 2019-03-21 | 2023-03-02 | City Of Hope | Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl |
| CA3139319A1 (en) * | 2019-05-07 | 2020-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| US20230072955A1 (en) * | 2020-01-23 | 2023-03-09 | Exuma Biotech Corp | Chimeric antigen receptors to her2 and methods of use thereof |
| EP4146271A4 (en) | 2020-05-06 | 2024-09-04 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A |
| CA3184449A1 (en) * | 2020-05-22 | 2021-11-25 | GC Cell Corporation | Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN112481284B (zh) * | 2020-12-07 | 2023-07-25 | 深圳瑞吉生物科技有限公司 | 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用 |
| WO2022187182A1 (en) * | 2021-03-02 | 2022-09-09 | The Trustees Of The University Of Pennsylvania | Targeting t regulatory cells to islet cells to stall or reverse type 1 diabetes |
| US12377144B2 (en) | 2021-03-03 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen |
| US20240366662A1 (en) | 2021-03-30 | 2024-11-07 | City Of Hope | Car t cell therapy and ifn gamma |
| WO2023274385A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向her2的通用型car-t细胞及其制备方法 |
| WO2023010122A2 (en) | 2021-07-29 | 2023-02-02 | Sonoma Biotherapeutics, Inc. | Synovial extracellular matrix-specific chimeric antigen receptor for targeting regulatory t cells to treat autoimmune diseases |
| JP2024531475A (ja) * | 2021-08-24 | 2024-08-29 | 賽斯尓▲チン▼生物技術（上海）有限公司 | Ｔ細胞製品およびその使用 |
| CN116023491A (zh) | 2021-10-25 | 2023-04-28 | 江苏众红生物工程创药研究院有限公司 | 抗cd26抗体及其应用 |
| WO2023172514A1 (en) * | 2022-03-07 | 2023-09-14 | Catamaran Bio, Inc. | Engineered immune cell therapeutics targeted to her2 and methods of use thereof |
| EP4490271A1 (en) | 2022-03-10 | 2025-01-15 | City of Hope | Membrane-bound il-12 for cellular immunotherapy |
| AU2023248529A1 (en) * | 2022-04-08 | 2024-10-24 | Fate Therapeutics, Inc. | Chimeric antigen receptor for tumor targeting |
| CN119256075A (zh) * | 2022-04-08 | 2025-01-03 | 菲特治疗公司 | 具有实体瘤靶向骨架的细胞及其用途 |
| CN114805584B (zh) * | 2022-06-30 | 2022-09-09 | 上海优替济生生物医药有限公司 | 抗原结合蛋白及其用途 |
| MX2025012753A (es) | 2023-04-27 | 2026-02-03 | Vanudis GmbH | Receptor de antigeno quimerico de correceptor |
| WO2025101672A1 (en) | 2023-11-06 | 2025-05-15 | City Of Hope | Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers |
| CN117924518B (zh) * | 2024-01-05 | 2025-08-22 | 苏州艾凯利元生物科技有限公司 | 用于nk细胞的嵌合抗原受体及工程化的nk细胞 |
| WO2025184170A1 (en) | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Methods and compositions for improving t cell function in an immunosuppressive environment |
| WO2025217175A1 (en) * | 2024-04-08 | 2025-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Engineering immune cells to migrate to, infiltrate, persist, and expand in solid tumors |
| WO2025235801A1 (en) | 2024-05-08 | 2025-11-13 | City Of Hope | Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1171468B1 (en) * | 1999-04-09 | 2008-07-02 | Universität Zürich | Method for the Stabilization of Chimeric Immunoglobulins or Immunoglobulin Fragments, and Stabilized Anti-EGP-2-scFv Fragment |
| KR20110050567A (ko) | 2004-07-22 | 2011-05-13 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| KR20100021601A (ko) | 2007-05-14 | 2010-02-25 | 바이오겐 아이덱 엠에이 인코포레이티드 | 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법 |
| CN103298935A (zh) * | 2007-08-15 | 2013-09-11 | 阿穆尼克斯公司 | 用于改善生物活性多肽性能的组合物和方法 |
| ES2717629T3 (es) * | 2009-11-03 | 2019-06-24 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas |
| US9586996B2 (en) * | 2010-04-30 | 2017-03-07 | Esperance Pharmaceuticals, Inc. | Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use |
| US8491908B2 (en) | 2010-06-01 | 2013-07-23 | Canon Kabushiki Kaisha | Composite particle, contrast agent for photoacoustic imaging, and method for producing the composite particle |
| WO2012050374A2 (en) | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunotherapy for solid tumors |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| RU2688185C2 (ru) | 2011-03-23 | 2019-05-21 | Фред Хатчинсон Кэнсер Рисерч Сентер | Способ и композиции для клеточной иммунотерапии |
| CN103596982B (zh) * | 2011-06-06 | 2016-11-02 | 诺沃—诺迪斯克有限公司 | 治疗性抗体 |
| KR102264290B1 (ko) * | 2012-08-20 | 2021-06-10 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법을 위한 방법 및 조성물 |
| EP2904004B1 (en) | 2012-10-04 | 2018-11-21 | Research Development Foundation | Serine protease molecules and therapies |
| WO2014055657A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US9492563B2 (en) * | 2012-10-30 | 2016-11-15 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| JP2016520586A (ja) * | 2013-05-08 | 2016-07-14 | ザイムワークス，インコーポレイテッド | 二重特異性ｈｅｒ２およびｈｅｒ３抗原結合性構築物 |
| US10808035B2 (en) | 2013-08-26 | 2020-10-20 | Markus Chmielewski | Anti CD30 chimeric antigen receptor and its use |
| CN107074957B (zh) * | 2014-01-13 | 2021-05-07 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| CN106459924A (zh) | 2014-04-23 | 2017-02-22 | 得克萨斯州大学系统董事会 | 用于疗法中的嵌合抗原受体(car)及其制备方法 |
| US11197919B2 (en) * | 2015-11-04 | 2021-12-14 | City Of Hope | Chimeric antigen receptors targeting HER2 |
-
2016
- 2016-11-04 US US15/773,754 patent/US11197919B2/en active Active
- 2016-11-04 KR KR1020187015769A patent/KR20180083874A/ko not_active Ceased
- 2016-11-04 BR BR112018009129-4A patent/BR112018009129A2/pt not_active IP Right Cessation
- 2016-11-04 CN CN202211409883.2A patent/CN116063574A/zh active Pending
- 2016-11-04 JP JP2018543279A patent/JP6932709B2/ja not_active Expired - Fee Related
- 2016-11-04 RU RU2018118817A patent/RU2753695C2/ru active
- 2016-11-04 AU AU2016349722A patent/AU2016349722A1/en not_active Abandoned
- 2016-11-04 EP EP22157943.6A patent/EP4074731A1/en not_active Withdrawn
- 2016-11-04 WO PCT/US2016/060724 patent/WO2017079694A2/en not_active Ceased
- 2016-11-04 CA CA3004306A patent/CA3004306A1/en active Pending
- 2016-11-04 MX MX2018005674A patent/MX2018005674A/es unknown
- 2016-11-04 CN CN201680076412.0A patent/CN108779174B/zh not_active Expired - Fee Related
- 2016-11-04 EP EP16863128.1A patent/EP3371227B8/en active Active
- 2016-11-04 ES ES16863128T patent/ES2909973T3/es active Active
-
2018
- 2018-05-03 IL IL259120A patent/IL259120B/en unknown
- 2018-05-04 MX MX2022013498A patent/MX2022013498A/es unknown
-
2021
- 2021-08-18 JP JP2021133074A patent/JP7264954B2/ja active Active
- 2021-12-06 US US17/543,148 patent/US20220265796A1/en not_active Abandoned
-
2022
- 2022-01-10 AU AU2022200116A patent/AU2022200116A1/en not_active Abandoned
- 2022-04-13 IL IL292222A patent/IL292222A/en unknown
-
2023
- 2023-04-13 JP JP2023065384A patent/JP2023100653A/ja not_active Withdrawn
-
2024
- 2024-10-18 US US18/919,692 patent/US20250333471A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500894A5 (enExample) | ||
| RU2018118817A (ru) | Химерные рецепторы антигена, нацеленные на her2 | |
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| IL292650A (en) | Chimeric antigen receptor T cells target il13ra2 | |
| TWI710572B (zh) | 改善配對的ｔ細胞受體 | |
| JP2017537627A5 (enExample) | ||
| RU2018113510A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| ES2833162T3 (es) | Receptor de antígeno quimérico y su uso | |
| RU2685479C2 (ru) | Химерный антигенный рецептор | |
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| ES2959480T3 (es) | Acoplador de células T - antígeno trifuncional y métodos y usos del mismo | |
| JP2015518479A5 (enExample) | ||
| JP2017500869A5 (enExample) | ||
| CN116970630A (zh) | 用于细胞治疗的组成型活性细胞因子受体 | |
| RU2016143384A (ru) | Трансгенные генетические метки и способы применения | |
| JP2016520074A5 (enExample) | ||
| JP2018509163A5 (enExample) | ||
| CN108779160A (zh) | 施用工程化t细胞以治疗中枢神经系统中的癌症 | |
| JP2016538855A5 (enExample) | ||
| JP2017538401A5 (enExample) | ||
| JPWO2020014366A5 (enExample) | ||
| JP2019512251A5 (enExample) | ||
| CN104177499A (zh) | 一种嵌合抗原受体、编码基因、表达载体及其应用 | |
| CN105802909B (zh) | 具有her2特异性tcr的t细胞制备物及其用途 | |
| Crowley et al. | Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH |